TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from OncoSil Medical Ltd ( (AU:OSL) ).
OncoSil Medical Ltd announced that the preliminary results of its PANCOSIL Phase 1-2 trial will be presented at the CIRSE Annual Congress in September 2025. The trial, conducted by Amsterdam University Medical Center, evaluates the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer. The study aims to simplify the administration of the OncoSil™ device, potentially enhancing market penetration and clinical use. The announcement aligns with OncoSil’s expectations for releasing initial trial results in the September 2025 quarter.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a global medical device company specializing in interventional oncology, focusing on improving cancer treatment outcomes through targeted intratumoural placement of Phosphorous-32 (32P) Microparticles. The company’s OncoSil™ device is designed for treating unresectable locally advanced pancreatic cancer, offering a targeted approach that delivers higher radiation doses directly to tumors while sparing surrounding organs. The device has received CE Marking approval and is designated as a breakthrough device in Europe and the United States, with approval for sale in over 30 countries.
Average Trading Volume: 40,709
Technical Sentiment Signal: Sell
Current Market Cap: A$21.08M
Learn more about OSL stock on TipRanks’ Stock Analysis page.